A phase II trial of Tocilizumab in anti-TNF refractory patients with JIA associated uveitis.
Phase of Trial: Phase II
Latest Information Update: 08 Jun 2016
At a glance
- Drugs Tocilizumab (Primary)
- Indications Uveitis
- Focus Therapeutic Use
- Acronyms APTITUDE
- 11 Dec 2015 Accrual to date is 4% according to United Kingdom Clinical Research Network.
- 01 Dec 2015 Status changed from not yet recruiting to recruiting, according to United Kingdom Clinical Research Network record.
- 11 Jun 2015 New trial record